fbpx JLABS Company News | JLABS

News


Other news

Want to know more about the JLABS Portfolio?

By JLABS

Read full story

Lung Cancer Innovation QuickFire Challenge

Jlab_Quickfire-2018-06-12
lung cancer
Challenge ended

$750,000 (¥4.7M) in Grants + Residency + Mentoring

Surgical Oncology
Therapeutics

                        点击这里阅读中文

Awardees

Lung%20Cancer%20Innovation%20QFC%20Awardees.png

 

DNX Biopharmaceuticals

 

DNX Bio is a biopharmaceutical company developing long-acting therapeutic proteins for the treatment of patients with life-long diseases. Founded in 2014 and headquartered in Irvine, CA, USA, DNX is pursuing the development of new therapeutic proteins utilizing a 21st century, half-life extension platform technology known as PASylation, which is in-licensed from XL-protein GmbH. XLp has granted DNX a worldwide exclusive license under its patents and know-how related to the PASylation technology to develop and commercialize several PASylated products.

 

Hawkeye Bio

 

Hawkeye Bio was launched in 2018 in California to commercialize novel, clinically validated breath analytics for the detection of lung cancer. Lung cancer is the leading cause of cancer deaths among both men and women[1]. Lung cancer often has no symptoms until it has metastasized, because there are few specialized nerves (pain receptors) in the lungs. Lung cancer is diagnosed late 84% of the time, when treatment options are more limited. Despite progress in biomarker discovery and targeted therapy, lung cancer mortality remains unacceptably high worldwide. Hawkeye’s mission is lung cancer interception to bring about a solution to this problem.

 

NE Scientific

 

NE Scientific is a Boston-based startup company developing a surgical guidance software for supporting physicians in targeting tissues during the percutaneous ablation of liver and lung tumors. The Accublate (TM) guidance software simulates in real-time the physics taking place during the ablation and determines the ablation volume in a patient-specific way. This information is generated intraoperatively and overlaid to CT images of the patient, helping the physician in achieving a complete treatment of all malignant tissues.

[1]HawkeyeBio.com, 2019

The Challenge

Image Paragraph

The average person breathes in 432 liters of oxygen every single day, a vital component in sustaining the trillions of cells in the body. Humans can survive just a few minutes without oxygen.  To that end, it is essential that we protect our lungs.  

Is there a way to cleanse the lungs after exposure to carcinogens much like a toothbrush cleanses the mouth after eating? Is there a way to shield the lungs from carcinogens much like sunscreen shields us from damaging UV exposure?  These are a few of the provocative ideas Johnson & Johnson Innovation hopes to trigger through the Lung Cancer Innovation QuickFire Challenge. 

Lung cancer is a major cause of global morbidity and mortality with approximately 1.6 million deaths globally each year.  Unlike other diseases, lung cancer is caused by prolonged environmental exposure to carcinogens that overwhelm a human’s natural defenses and result in inflammation, genomic changes and ultimately tumor growth.  Although a global epidemic, it is unclear what makes one individual over another more susceptible to developing lung cancer.  

Johnson & Johnson (China) Investment Ltd. and Johnson & Johnson Innovation LLC are committed to prioritizing lung health.  How do we leverage the totality of science and technology to achieve comprehensive lung health -  to ultimately prevent, intercept and cure lung cancer?

Up to three innovators with the best ideas, technologies, or solutions that improves human healthcare related to preventing, intercepting or curing lung cancer will be awarded up to a total of $750,000 in grants, a voucher for one year of residency at JLABS @ Shanghai (optional), including a laboratory bench, workstation and access to the JLABS community, and mentorship from Johnson & Johnson Innovation and/or its affiliates.

Reward

Up to $750,000 (¥4,775,850) in total grants 
  • 1 year residency at JLABS @ Shanghai (Optional)
  • Mentoring & coaching from experts from Johnson & Johnson Innovation and/or its affiliates

Areas of Interest

We encourage applications from innovators working on all aspects of lung health, including solutions focused on Lung Cancer:

  • Prevention: Approaches to identify risks and for warding off onset of lung cancer
  • Interception: Arrest lung cancer as it develops, prior to clinical onset
  • Cures: Completely eliminate presence of lung cancer and reverse damage to restore full health

Please keep in mind that no idea is too big or too early for consideration. Applications that clearly describe a concept or path forward to achieve these goals will also be considered during evaluation.  

We are interested in applications addressing the full spectrum of lung health. Specific areas of interest include, but are not limited to: 

  • To develop approaches to reduce, prevent, or protect from exposure to respiratory carcinogen, including novel approaches to smoking cessation 
  • To develop approaches to measure the exposure to and biological effect from respiratory carcinogens
  • To develop diagnostics/biomarkers to detect pre-cancers or early-stage malignant lesions
  • To develop approaches, including surgical, medical, behavioral, digital or others, to prevent or intercept lung carcinogenesis
  • To discover new tools for diagnosis and extirpation of curable lung cancers
  • To develop new treatments or treatment modalities for the cure of lung cancer

Approaches should include the following areas:

  • Pharmaceuticals
  • Consumer products
  • Medical devices
  • Global public health
  • Health technologies
  • Cross-sector initiatives – an integration of one or more the aforementioned areas of focus 

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

Timeline

June 14, 2018 (China Time)
Applications Open
September 21, 2018 (China Time)
Submission Deadline
Spring 2019
Winner Announcement at JLABS @ Shanghai Launch

Apply Now


Don’t miss the deadline

Why this challenge matters to us

We believe a good idea can come from anywhere, and it’s our goal to find new and innovative technologies that provide solutions to patients from across the world. Working together, we can spark the next great idea that will change the trajectory of health.

FAQs

 

Q: What if I’m having trouble accessing the portal/website?

A: Make sure your browser is up to date and accepting cookies. You can contact customer service at [email protected] if you are having technical difficulties as well.

 

Q: Is residency at JLABS @ Shanghai required?

A: No. Residency is encouraged but optional.

 

Q: Do I need to reside in Shanghai or a Chinese entity in order to apply?

A: No. We are seeking innovations globally.

 

Q: For prizes involving residency at JLABS, what does that entail and for how many people?

A: For challenges involving residency at JLABS, that entails 1 lab bench and 1 workstation (desk) for 2 people maximum. If you have more employees, additional footprint can be rented.

 

Q: For prizes involving residency at JLABS, are there any expenses not covered by JLABS?

A: Each applicant will be required to submit to a background check, which is subject to a minimal fee.  We also collect a deposit that is refundable at the end of the lease term. There may be other expenses, but this will be dependent on the work that the company is doing in JLABS.  There may also be fees associated with EH&S waste, specialty equipment, printing and phone calls.

 

Q: Will JLABS pay for my living costs, relocation or visas?

A: No, any additional fees and paperwork are up to the winner.

 

Q: Can I submit supporting documents (for example a video) as part of my application? 

A: You will have the opportunity and are encouraged to upload supporting materials such as slide decks, research papers, and videos as part of your application. You may submit a video along with your typed responses. Maximum length is 2 minutes.

 

Q: Is it ok if some of the information I submit is confidential?

A: Do not submit confidential information. Only non-confidential information should be submitted and anything you submit will be treated as non-confidential.

 

Q: What happens with IP (Intellectual Property)?

A: As this is a no strings attached arrangement, JLABS does not acquire any IP.  Any IP creation and/or protection remains the sole responsibility of the inventors.

 

Q: Is a patent required to apply?

A: No, a patent is not required to apply.  However, you should not submit any information that you wish to keep confidential or that may negatively impact upon the future patentability of your invention.

 

Q: What kind of science / technology is appropriate for the Challenges? 

A: We encourage all to apply. Find out more about what areas we desire to explore here: https://www.jnjinnovation.com/partnering

 

Q: Who is eligible to apply?

A: Each Challenge has its own terms & conditions that can be found prior to filling out the application.

 

Q: What are the specific criteria for application?

A:  Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential impact
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Idea submission outlines interest in the innovation ecosystem in Shanghai (optional)

 

Q: Who can I contact if I have questions about the Challenges or the application process?

A: Please contact [email protected] with any questions.

 

Q: Where do I apply? And do I have to complete the application in one sitting?

A: Apply at https://jlabs.jnjinnovation.com/form/lung-qfc-apply. You are able to save your work and log back in to finish at a later time if needed.

About Johnson and Johnson Innovation, JLABS

Picture1.png

 

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit jlabs.jnjinnovation.com.

About Johnson & Johnson (China) Investment Ltd

Picture1_0.png

 

 

 

 

强生公司

强生是全球业务分布广泛、综合性的跨国医疗保健企业,业务涉及消费品、制药、医疗器材三大领域,1985年在华创立了第一家合资企业。强生遵循企业信条的价值观,致力于践行“关爱全世界,关注每个人”的健康愿景,以领先的科技研发创造创新的理念、产品和服务,为改善人类健康和福祉而不懈努力。每天,强生遍布世界各地的员工,与他们的合作方一起,为全球消费者和病患带来更健康、更快乐、更长寿的生活。

 

 


 

JLABS @ M2D2 QuickFire Challenge

JLABS @ M2D2 QuickFire Challenge
Challenge ended

Residency at JLABS @ M2D2

Diabetes
Neurovascular
Orthopedics
Surgery
Vision care
Image paragraph

Third Pole is producing next generation cardio-pulmonary therapies that expand patient access. Our first product creates inhaled nitric oxide on-demand, on-site from air. Powered by this innovative portable technology licensed from Massachusetts General Hospital we eliminate the need for cumbersome compressed gas cylinders and enable the worldwide use of inhaled NO in settings outside of acute care.

The Challenge

We are looking for game-changing early-stage medical device innovations and therapeutic platforms across Johnson & Johnson’s strategic areas of interest:

  • Cardiovascular
  • Diabetes
  • Neurovascular
  • Orthopedics
  • Surgery
  • Vision Care

Entrants must be committed to conducting their project at the M2D2 space in Lowell, MA.

Rewards and benefits

Space at JLABS @ M2D2

Why this challenge matters to us

At Johnson & Johnson Innovation, we believe the next great idea can come from anywhere – and that it’s just as likely to come from outside of our walls as from inside our research labs. That’s why Johnson & Johnson Innovation is excited to announce JLABS @ M2D2, our accelerator initiative in partnership with the northeast region’s premier medtech incubator, University of Massachusetts Medical Device Development Center (M2D2) in Lowell, Massachusetts. JLABS @ M2D2 is our seventh JLABS facility and the first specifically focused on the early-stage medical device ecosystem.

Timeline

PST
Deadline to apply
PST
Announcement of winners

Check out the blog post on the J&J website!

CDI @ TMC QuickFire Challenge

CDI @ TMC QuickFire Challenge
Challenge ended

Up to $400,000 USD*

Obesity
Osteoarthritis
Surgical Oncology

Winners

smc_qfc_mtc_allwinnersv2.jpg

Image paragraph

LifeSprout is developing the next-generation of synthetic soft tissue substitutes for aesthetic and oncologic restoration.

Image paragraph

Intelligent Implants enhance, directs and monitors bone growth in real-rime using wireless implantable electronics.

Barostitch is a first-of-its-kind medical device for the minimally invasive, no-touch closure of calcified, large-bore femoral artery access sites following structural heart interventions.

The Challenge

Image paragraph

In conjunction with the Grand Opening of the Center for Device Innovation (CDI @ TMC) in the Fall 2017, Johnson & Johnson Innovation and Johnson & Johnson Medical Devices have launched the CDI @ TMC QuickFire Challenge, a device-focused challenge aimed at game-changing early-stage medical device innovations across strategic areas of interest for Johnson & Johnson Medical Devices, with an emphasis on Surgical Oncology and/or Obesity.


Johnson & Johnson Innovation will award a grant up to $50,000 to the top solutions, one year of paid lab space at JLABS @ TMC in Houston, Texas, including access to the device prototyping lab, and  mentorship and coaching from Johnson & Johnson Medical Devices experts including the world renowned Billy Cohn. Additionally, Johnson & Johnson Innovation has partnered with angelMD, an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners to provide the winning solution an additional $100,000 investment from its catalyst fund, plus angelMD will feature the top finalists on its web platform for syndicate partners to invest up to an additional $250,000.


Applications open Tuesday, April 25 and the deadline to apply is Wednesday, June 28, 2017. Winners will be announced at The MedTech Conference in San Jose, CA September 25-27, 2017.

Rewards and benefits

Up to $400,000 USD*
  • *in grants for multiple winners
  • Entrance to an available JLABS
  • Mentoring & Coaching

QuickFire Challenge innovation focus areas

This QuickFire Challenge is looking for companies with a focus on Surgical Oncology and / or Obesity, however, other device companies that align with strategic areas of interest for Johnson & Johnson Medical Devices will be considered. Areas of interest include:

Surgical Oncology - Improved treatment options with reduced complications and better outcomes, Minimally invasive procedures

Image paragraph

Obesity - More durable interventions across the continuum, Prevent or reduce morbidities of obesity

Image paragraph

Osteoporosis - Minimize OP fracture rate, improve healing and address fragile bone

Image paragraph

Osteoarthritis - Early interventions to prevent progression, Better surgical outcomes in advanced disease

Image paragraph

Cardiovascular - Durable, effective interventions to improve outcomes in AFIB and structural heart conditions (e.g. CHF)

Image paragraph

Timeline

EST
Challenge Opens
EST
Submission Deadline
PST
Winners announced at The MedTech Conference in San Jose, September 25-27, 2017

Why this challenge matters to us

The Johnson & Johnson Medical Devices have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it’s our goal to break through the noise of the crowded device landscape and find new and innovative technologies that provide minimally invasive solutions to patients.

Application Process

Solutions will be evaluated by a panel of reviewers and judges on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes in a strategic area of interest
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has nine locations in innovation hot spots across North America and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto and a new JLABS @ NYC (in collaboration with the New York Genome Center -opening in 2018).  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.


About Johnson & Johnson Medical Devices

Making significant contributions to surgery for over a century, the Johnson & Johnson Medical Devices Companies are in the business of reaching more patients and restoring more lives. We represent the most comprehensive surgical technology and specialty solutions business worldwide, offering an unparalleled breadth of products, services, programs and research and development capabilities directed at advancing patient care while delivering clinical and economic value to health care systems.


About the Center for Device Innovation @ TMC

The Center for Device Innovation @ Texas Medical Center (CDI @ TMC) is a new collaboration (opening mid-2017) that aims to accelerate end-to-end development of breakthrough medical devices. CDI @ TMC will include multiple components to accelerate new medical technologies from concept through commercialization, including a medical device engineering studio housed at the TMC Innovation Institute. This state-of-the-art “maker space” will be home to R&D staff of the Johnson & Johnson Medical Devices Companies and will be used to accelerate both select internal projects and strategically aligned ventures of Johnson & Johnson Medical Devices.


About angelMD

angelMD is an investment platform and marketplace connecting innovative medical startups, physicians, investors, and industry partners. Leading physicians from all over the US have joined the angelMD Scientific Advisory Board and Leaders Club to help source, evaluate and advise companies in biotechnology, medical device and healthcare technology. For more information, visit www.angelmd.co.

Victorian QuickFire Challenge: Driving Device Innovation

Victorian QuickFire Challenge: Driving Device Innovation
Challenge ended

Up to AUD 300,000*

Neurovascular
Obesity
Orthopedics

Winners

  • Atmo Biosciences: Australia-based Atmo Biosciences has developed a patented, low-cost, non-invasive medical device in the form of an ingestible electronic capsule. The device gathers digital health data from gas concentrations as it passes through the gut, for the screening and diagnosis of gastrointestinal disorders and for assessing effects of dietary treatments on the gut.
  • RMIT University: An Australia-based RMIT University team led by Madhu Bhaskaran has developed electronics that stretch and flex, driving the development of ultra-light, stretchable, wearable sensors. The team’s transparent, unbreakable patch has been demonstrated for ultra-violet (UV) sensing and can be potentially integrated with clothing or worn on skin. The patch can quantitatively track the amount of UV radiation and exposure (both UVA and UVB).
  • Spect Inc.

The Challenge

Image paragraph

Medical Device Innovators are invited to bring their ideas to the growing hub for scientific innovation in the state of Victoria, Australia through the Victorian QuickFire Challenge: Driving Device Innovation. Victoria has one of the world's largest life science clusters composed of medtech, biotech and pharmaceutical industries. The sector employs more than 23,000 people and is made up of more than 650 firms ranging in size from small start-ups to large Victorian exporters and global manufacturers. Revenue in the sector has quadrupled since 2003 to $12.7 billion and exports have doubled since 2011 to $1.3 billion.

This device-focused QuickFire Challenge, announced by the Victorian Government in collaboration with Johnson & Johnson Innovation, is aimed at game-changing early-stage medical device innovations across strategic areas of interest for Johnson & Johnson Medical Device Companies

The Victorian Government will award up to AUD 300,000 to the top solutions including access to the device prototyping lab and mentorship and coaching from Johnson & Johnson Medical Device experts.

Specific areas of focus include:

  • 3D Printing: Using new technologies to deliver 3-D printing solutions that can have transformative applications
  • Biomaterials
  • Cardiovascular: Durable, effective interventions to improve outcomes in AFIB and structural heart conditions (e.g. CHF)
  • Digital Surgery: Emerging technologies in surgical robotics
  • Neurovascular: Innovative therapies for stroke patients
  • Oncology:  Solutions designed to assist with the monitoring, physiotherapy and invasive care of oncology patients
  • Obesity: More durable interventions across the continuum, Prevent or reduce morbidities of obesity
  • Orthopedics: Joint Reconstruction, Trauma, Spine and Sports Medicine. Collectively, these businesses are focused on helping patients along the care continuum — from early intervention to surgical replacement, with the goal of helping people return to living active and fulfilling lives.
  • Osteoarthritis:  Early interventions to prevent progression, Better surgical outcomes in advanced disease
  • Osteoporosis: Minimize OP fracture rate, improve healing and address fragile bone
  • Sensor Technologies: Implantable and wearable sensors: Innovative approaches to healthcare monitoring.
  • Surgery: Advancing technologies, products and services to enhance patient care and bring greater precision to every aspect of surgery.
  • Vision Care: Creating life-long solutions to vision care needs

Why this challenge matters to us:

The Johnson & Johnson Medical Device Companies have a successful history in creating new markets, delivering breakthrough innovation and establishing strong partnerships built on a shared vision. We believe a good idea can come from anywhere, and it's our goal to break through the noise of the crowded device landscape and to accelerate the development of novel technologies to provide solutions to patients.

Application process:

Solutions will be evaluated by a panel of industry and government reviewers on their ability to meet the following criteria:

  • Potential to impact healthcare outcomes in a strategic area of interest
  • Uniqueness of solution & level of competition in current market
  • Quality & feasibility of technology
  • Team credibility & capabilities
  • Clarity of plan: Milestones & defined go/no go decisions

Rewards and benefits

Up to a total of AUD 300,000 in funding to help advance their research*
  • Access to a network of Johnson & Johnson Innovation experts
  • *Up to AUD 300,000 will be shared between up to three (3) winners for projects in the field of medical devices in the form of a grant agreement with the Victorian Government for payment for goods and services obtained within Victoria.

Timeline

Launch at the 6th Annual Devices & Diagnostics Lab
Application Deadline
Review Start
Review End
Review Call
Finalist Presentations
Fall 2018
Winner Announcement

Apply Now

Submit your idea today!


Don’t miss the deadline

About Victoria

The Victorian Government is working to sustainably develop the economy by growing employment and improving the lives and prosperity of all Victorians.

Since the release of our Medical Technologies and Pharmaceuticals Sector Strategy, we have provided key support to the industry and manufacturing through the $200 million Future Industries Fund.

Global health care spending is projected to grow by over four per cent per year, so there is an urgent need for new technologies and diagnostic tools that will improve patient care.

Through start-up initiatives such as MedTech's Got Talent, the new MedTech Actuator and BioCurate we are working to capitalise upon this enormous opportunity for Victoria's booming medtech and pharmaceutical sector, which currently employs more than 23,000 and brings in $12.7 billion in annual revenue.

Last year we opened a new Victorian Government Trade and Investment office in Boston, to help Victorian businesses connect with the investors that can take promising products and business ideas to the next level.

Continuing to grow the sector by attracting talent, supporting start-ups, and strengthening relationships between researchers and global industry will create rewarding, secure jobs for Victorians and help us to play a key role in improving health and wellbeing worldwide.

About Johnson & Johnson Innovation, JLABS

Johnson & Johnson Innovation, JLABS (JLABS) is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-saving, life-enhancing health and wellness solutions to patients around the world. JLABS achieves this by providing the optimal environment for emerging companies to catalyze growth and optimize their research and development by opening them to vital industry connections, delivering entrepreneurial programs and providing a capital-efficient, flexible platform where they can transform the scientific discoveries of today into the breakthrough healthcare solutions of tomorrow.  At JLABS we value great ideas and are passionate about removing obstacles to success to help innovators unleash the potential of their early scientific discoveries.  JLABS is a no-strings-attached model, which means entrepreneurs are free to develop their science while holding on to their intellectual property.  JLABS is open to entrepreneurs across a broad healthcare spectrum including pharmaceutical, medical device, consumer and digital health sectors.

JLABS currently has locations in innovation hot spots across the world and produces entrepreneurial programs and campaigns to seek out the best science, like the QuickFire Challenges around the globe. The JLABS flagship opened in 2012 in San Diego at Janssen's West Coast Research Center, and since then, has established two locations in San Francisco - one through a collaboration with the California Institute for Quantitative Biosciences (QB3) and a second standalone facility in South San Francisco.  JLABS is also located in Boston through a collaboration with LabCentral, in Lowell, Massachusetts through a collaboration with UMass, in Houston through a collaboration with the Texas Medical Center (TMC), in Toronto through a collaboration with the Ontario Government and the University of Toronto. New JLABS in NYC and Shanghai have been announced, and in February 2018, the Belgium-based JLINX incubator began transitioning into a JLABS, making this the first JLABS in Europe.  For more information about JLABS, please visit www.jlabs.jnjinnovation.com.

About Johnson & Johnson Innovation

Johnson & Johnson Innovation LLC focuses on accelerating all stages of innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's global healthcare businesses. Johnson & Johnson Innovation provides scientists, entrepreneurs and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device and consumer companies of Johnson & Johnson. Under the Johnson & Johnson Innovation umbrella of businesses, we connect with innovators through our regional Innovation Centers, Johnson & Johnson Innovation | JLABS, Johnson & Johnson Innovation - JJDC, Inc. and our Business Development teams to create customized deals and novel collaborations that speed development of innovations to solve unmet needs in patients. For more information, visit www.jnjinnovation.com or follow @JNJInnovation.

Image paragraph
Image paragraph

Proudly supported by the Victorian Government